Mineralys CMO sells 14,474 shares in Form 4
Mineralys Therapeutics Chief Medical Officer David Malcom Rodman reported a mix of option exercises and share sales in mid-June.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Mineralys Therapeutics Chief Medical Officer David Malcom Rodman reported a mix of option exercises and share sales in mid-June. On June 15 and June 17, he sold a total of 14,474 shares of common stock in open-market transactions at weighted-average prices around $23.81 and $25.00.
To support these sales, he exercised stock options covering 8,126 shares at exercise prices of $10.20, $14.25 and $15.44. After the transactions, he directly holds 57,095 shares of common stock. The filing notes that the trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on October 6, 2025.
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
8 txns
Insider
Rodman David Malcom
Role
Chief Medical Officer
Sold
14,474 shs ($350K)
Approx. gross sale proceeds
$350K
Approx. exercise cost
$102K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 4,167 | $0.00 | $0.00 |
| Exercise | Stock Option | 417 | $0.00 | $0.00 |
| Exercise | Common Stock | 4,167 | $14.25 | $59K |
| Exercise | Common Stock | 417 | $15.44 | $6K |
| Sale | Common Stock | 4,584 | $25.00 | $115K |
| Exercise | Stock Option | 3,542 | $0.00 | $0.00 |
| Exercise | Common Stock | 3,542 | $10.20 | $36K |
| Sale | Common Stock | 9,890 | $23.8106 | $235K |
Holdings After Transaction:
Stock Option — 200,418 contracts (Direct);
Common Stock — 57,095 shares (Direct)
Footnotes (4)
- F1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.
- F2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $23.41 to $23.98. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
- F3. The stock option vests in monthly installments over a period of four years, with 1/48th of the total shares underlying the option vesting each one-month period following the date of grant.
- F4. The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.
Key Figures
Shares sold: 14,474 shares
Options exercised: 8,126 shares
Sale price June 15: $23.8106/share
+4 more
7 metrics
Shares sold
14,474 shares
Total common shares sold in June transactions
Options exercised
8,126 shares
Common shares acquired via option exercises
Sale price June 15
$23.8106/share
Weighted-average sale price on June 15
Sale price June 17
$25.00/share
Reported sale price on June 17
Exercise price
$10.20/share
Stock option exercise price for 3,542 shares
Exercise prices
$14.25 & $15.44/share
Additional stock option exercise prices
Shares held after
57,095 shares
Direct common stock holdings after transactions
Key Terms
Rule 10b5-1 trading plan, weighted-average price, stock option, open-market sale, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted-average price financial
"The price reported in Column 4 is a weighted-average price."
Weighted-average price is the average of multiple prices where each price is counted according to its size or importance—larger trades carry more weight than smaller ones, like averaging course grades by credit hours. It matters to investors because it gives a more realistic picture of the true price paid or received, helping assess trade execution, compare performance, calculate cost basis, and value positions more accurately than a simple average.
stock option financial
"The stock option vests in monthly installments over a period of four years"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
derivative exercise/conversion financial
"transaction_action": "derivative exercise/conversion""
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Mineralys Therapeutics (MLYS) report for its CMO?
Mineralys Therapeutics’ Chief Medical Officer David Malcom Rodman exercised stock options and sold common shares. He sold 14,474 shares in open-market trades and exercised options for 8,126 shares, ending with 57,095 shares held directly after the reported transactions.
What stock options did the Mineralys Therapeutics (MLYS) CMO exercise?
He exercised options covering 8,126 Mineralys Therapeutics common shares. The underlying options had exercise prices of $10.20, $14.25 and $15.44 per share, converting those option rights into actual common stock as part of the reported transactions.
Were the Mineralys Therapeutics (MLYS) insider trades done under a Rule 10b5-1 plan?
Yes. The filing states the transactions were effected under a Rule 10b5-1 trading plan adopted on October 6, 2025. Such plans pre-schedule trades, helping separate routine portfolio management from discretionary timing decisions by insiders.
What do the weighted-average prices mean in the Mineralys Therapeutics (MLYS) Form 4?
A weighted-average price means the reported per-share price reflects multiple trades at slightly different prices. For one sale, shares were sold between $23.41 and $23.98, and the weighted-average figure summarizes those trades rather than listing each individual execution price.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates